Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
RH (RH)
Consensus Price Target: $208.88 (58.3% implied return)
Formerly known as Restoration Hardware, RH (NYSE: RH) is a specialty retailer that exclusively sells its own brand of high-end furniture and home decor.
Why Is RH Not Exciting?
- Disappointing same-store sales over the past two years show customers aren’t responding well to its product selection and store experience
- Falling earnings per share over the last three years has some investors worried as stock prices ultimately follow EPS over the long term
- 7× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
RH’s stock price of $131.91 implies a valuation ratio of 13.9x forward P/E. Check out our free in-depth research report to learn more about why RH doesn’t pass our bar.
Baldwin Insurance Group (BWIN)
Consensus Price Target: $30.22 (40% implied return)
Rebranded from BRP Group in May 2024, Baldwin Insurance Group (NASDAQ: BWIN) is an independent insurance distribution company that provides tailored insurance, risk management, and employee benefits solutions to businesses and individuals.
Why Are We Hesitant About BWIN?
- Free cash flow margin shrank by 10.7 percentage points over the last five years, suggesting the company stepped up its investments to maintain its competitive edge
- High net-debt-to-EBITDA ratio of 8× increases the risk of forced asset sales or dilutive financing if operational performance weakens
Baldwin Insurance Group is trading at $21.59 per share, or 10.5x forward P/E. Read our free research report to see why you should think twice about including BWIN in your portfolio.
Amphastar Pharmaceuticals (AMPH)
Consensus Price Target: $29 (49.9% implied return)
Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ: AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.
Why Does AMPH Fall Short?
- 5.4% annual revenue growth over the last two years was slower than its healthcare peers
- Revenue base of $719.9 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Costs have risen faster than its revenue over the last two years, causing its adjusted operating margin to decline by 6.4 percentage points
At $19.35 per share, Amphastar Pharmaceuticals trades at 5.5x forward P/E. If you’re considering AMPH for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
